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Summary 
Inflammatory arthritis are a group of auto-immune diseases characterized by a chronic 
inflammation of the joints. Rheumatoid arthritis, the most common form of arthritis, is 
associated with local joint destruction and systemic bone loss. Osteoclasts, the only cells of 
the body able to resorbe bone, are key players in these two types of bone loss. 
Bisphosphonates are analogues of pyrophosphate, inhibiting osteoclasts action and bone 
resorption. They are indicated in pathology associated with an excess of resorption. Besides 
their effect on bone they also exhibit extraosseous properties, acting on tumor cells, 
inflammation or angiogenesis. Thus, they have been trialed in the context of arthritis. It is 
now clear that they do not have any significant direct effect on disease activity or pain. If their 
indication in the systemic bone loss is clear, any beneficial effects on bone erosions are still 
controversial but interesting preliminary results warrant further investigations.  
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Introduction 
Bisphosphonates (BPs) are structural analogues of inorganic pyrophosphate widely used in 
clinical practice for the treatment of osteoporosis, bone metastasis, hypercalcemia or Paget's 
disease [1]. Their main effect is to prevent bone resorption by interfering with several 
metabolic processes needed for osteoclasts survival and function. In normal condition, a 
balance exists between bone resorption and construction. Osteoclasts, arising from the 
monocyte/macrophage lineage, remove mineralised bone, action which is followed by the 
formation and mineralisation of new bone matrix by the osteoblasts. In pathological 
conditions, such as osteoporosis or bone metastasis, an excess of osteoclast activity exists, 
leading to a net bone loss. BPs, inhibiting this excessive osteoclast activity, are then a logical 
strategy to treat those situations. Despite major advances in the understanding of the coupling 
mechanisms between osteoclasts and osteoblasts, for example with the discovery of the 
Receptor Activator of Nuclear factor Kappa-B (RANK) / RANK-ligand (RANKL) / 
Osteoprotegerin (OPG) system, the exact mechanisms underlying the crosstalk between these 
2 cells still need to be clarified and could lead to the discovery of new therapeutic targets. 
 
Besides their effect on bone, BPs have also extraskeletal actions, interfering with tumoral 
cells proliferation, angiogenesis or inflammation [2-4]. The antitumoral effect is partly 
indirect, via the inhibition of bone resorption and subsequently the release of bone-derived 
growth factors. A direct effect of BPs on tumor cells has also been shown in vitro when they 
are administered with cytotoxic agents although small volume of in vivo evidence for direct 
anti-tumour effects of BPS have been demonstrated. These preclinical results have permitted 
phase III clinical studies, in breast cancer for example where Zoledronate (ZA), a third 
generation BPs, has been shown to significantly decrease the risk of recurrence in all sites [5] 
Besides this anti-tumoral effect, BPs have also been shown to act on inflammation, 
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angiogenesis and pain. Although these additional effects remain more controversial with 
mainly in vitro data, they open the range of BPs indications for other pathologic conditions 
like inflammatory arthritis, hip osteonecrosis or neuroarthropathy [4]. 
 
Rheumatoid arthritis is the most common of inflammatory arthritis. It is an autoimmune 
disease characterised by a chronic inflammation of the joint and is associated with a clear 
imbalance between bone resorption and formation. RA is associated with a systemic bone loss 
leading to osteoporosis and joint destruction secondary to the local chronic inflammation [6]. 
Osteoclasts have been shown to be the major cell types involved in those two types of bone 
loss and could be targeted by BPs. Although some studies have also pointed out the potential 
interest of BPs in osteoarthritis, most of the data were negative or showed radiological but not 
clinical benefits [7]. The goal of this review is to summarise the current knowledge on the 
mechanisms of action and indications of BPs in rheumatoid arthritis. 
 
Mode of action of bisphosphonates 
BPs are used since four decades in the treatment of diseases associated with a high bone 
turnover. However, it is only recently that their mechanism of action has been unraveled. BPs 
are analogues to the inorganic molecule pyrophosphate chararacterized by a phosphore-
carbon-phosphore (P-C-P) structure. Importantly, this molecule is resistant to degradation, 
accounting for its long half-life when it binds to bone. The carbone molecule is linked to 2 
side chains known as R1 and R2. The radical R1 is usually a hydroxyl group and is 
responsible for the avidity of the molecule to the bone whereas R2 is associated with the anti-
resorptive capacity and is different for each type of BPs. According to this last radical, a BP is 
classified as simple (clodronate and etidronate) or nitrogen-containing (pamidronate, 
alendronate, ibandronate, risedronate and ZA) BP, the latter being the more potent. 
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The main cellular targets for BPs are osteoclasts. Indeed, the high and selective affinity of 
BPs to bone brings them in close contact with these cells during the resorption process. BPs 
are poorly absorbed from the gastrointestinal tract and about 50% of the absorbed drug is 
taken up selectively by the skeleton, while the rest is excreted unaltered in urine [7]. As 
already mentioned, their resistance to degradation enables them to stay in the bone for months 
or years where they are slowly released with the process of bone turnover. Osteoclasts are the 
only cells type able to degrade the bone. Originating from the monocyte/macrophage lineage, 
they undergo several steps of differentiation before being mature osteoclasts. The two main 
cytokines needed for this differentiation process are RANKL and Macrophage colony-
stimulating factor (M-CSF). After being recruted, osteoclasts precursors fuse to form 
multinucleated cells which attach to bone where they create a resorption lacunae. During this 
final resorption process, BPs are dissociated from the bone mineral by the acidic environment 
created by the osteoclasts within the resorption lacunae [9]. Then, the BP is taken up by the 
osteoclasts and interacts with different metabolism processes which differ depending on the 
type/presence of nitrogen within the molecule (Figure 1). 
 
The main mechanism of action of simple BPs is to interfere with ATP metabolism and induce 
cell apoptosis [9]. Their chemical structure, which closely resembles to Ppi, allows a 
condensation of a BP with an AMP to form an AppCp-type nucleotide instead of an ATP. 
This ATP analogue resembles to ATP but is resistant to hydrolytic breakdown. The 
intracellular accumulation of this non-hydrolysable ATP is likely to inhibit numerous 
intracellular metabolic enzymes, having a detrimental effect on cell function and eventually 
inducing apoptosis. It had been shown that the mitochondrial ADP/ATP translocase is one of 
the molecular pathways involved in this effect through activation of caspase-3 [10]. 
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Interestingly, the effect of those simple BPs on osteoclasts can be overcome by using caspase 
inhibitor. RANKL and TNF can also rescue the osteoclasts from BPs-induced apoptosis [11]. 
Sutherland et al. have recently shown that RANKL and TNF-alpha were also able to prevent 
apoptosis induced by the nitrogen-containing BP alendronate and clodronate by increasing the 
expression of the anti-apoptotic protein Mcl-1 by the osteoclasts [12]. The importance of 
those cytokines in the focal and systemic bone loss associated with arthritis could explain the 
lack of efficacy of BPs in this indication. 
 
Nitrogen containing BPs act mainly by inhibiting farnesyl pyrophosphate (FPP) synthase, a 
key enzyme in the mevalonate pathway. The mevalonate pathway produces isoprenoids that 
are vital for diverse cellular functions, ranging from cholesterol synthesis to growth control. 
FPP synthase catalyses the sequential condensation of dimethylallyl pyrophosphate (DMAPP) 
with 2 units of 3-isopentenyl pyrophosphate (IPP) to form FPP. This molecule is required for 
the prenylation (transfer of the isoprenoid group) of several proteins that is essential for their 
function and attachment to the cell membrane [13]. The main targeted proteins are the small 
GTPase signalling proteins such as Ras, Rho, Rac, Cdc42 and Rab families which regulate a 
variety of cell processes within osteoclasts like cytoskeletal arrangements, membrane ruffling, 
trafficking of intracellular vesicles and apoptosis. N-BPs inhibit another enzyme of the 
mevalonate pathway, the geranylgeranyl diphosphate synthase (GGPP), also involved in the 
prenylation of the small GTPase [14]. Finally, the inhibition of FPP synthase leads to the 
accumulation of IPP that becomes conjugated to AMP to form a novel ATP analogue (ApppI). 
This ATP analogue inhibit mitochondrial adenine nucleotide translocase leading to apoptosis 
[15]. 
 
Why targeting osteoclasts in arthritis? 
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Rheumatoid arthritis (RA) is the most common form of inflammatory arthritis and is 
characterized by a chronic inflammation of the joint. Bone loss is common during the 
progression of the disease and occurs inside the joint where chronic inflammation lead to 
osteoarticular destructions and related disability. Systemic bone loss favored by the chronic 
inflammation can also lead to osteoporosis and increase the risk of fracture. Osteoclasts are 
the principal cell type responsible for both focal and systemic bone loss in RA [16].  
 
Gravallese et al. first described TRAP positive multinucleated cells at the bone-inflammation 
interface in the joint of patients with inflammatory arthritis [17]. Several lines of evidence 
have since confirmed the role of osteoclasts in bone destruction during RA. Osteopetrotic 
mouse models such as RANKL-/- mice develop arthritis but display no bone erosion [18]. 
Treatment with a chimeric OPG fusion protein (Fc-OPG), which inhibits osteoclast 
differentiation, efficiently prevents bone erosion but not inflammation in the rat collagen-
induced arthritis model [19]. The origins of those osteoclasts remain unclear. They probably 
differentiate from monocytes/macrophages precursors, abundant in the inflamed synovial 
tissue in RA. This process is activated by cells present in the synovial tissue which express 
pro-osteoclastogenic factors. Indeed, synovial fibroblasts, as other inflammatory cells, are 
source of M-CSF and RANKL. Moreover, pro-inflammatory cytokines like TNF alpha, Il-6 
or IL-1 expressed by macrophages also promote osteoclasts differentiation. Finally, chronic 
inflammation has been shown to increase the number of osteoclast precursors in the systemic 
circulation and, then, the chance for these cells to be attracted by the chemokines within the 
joint [20]. 
 
Osteoclasts also play a major role in the systemic bone loss associated with inflammation. 
This complication is not only observed in inflammatory arthritis but is also a feature of all 
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chronic inflammatory disorders. For instance, patients with chronic inflammatory disease 
VXFKDV&URKQ¶VGLVHDVe or ulcerative colitis have a decrease of their BMD and an increased 
level of serum resorption markers [21]. This bone loss is correlated with the activity of the 
disease and serum markers of inflammation. Increase in the level of systemic pro-
inflammatory cytokines is the main mechanism driving to this bone loss. They increase the 
pool of osteoclast precursors coming from the bone marrow. For example, psoriatic arthritis 
patients exhibit a marked increase in osteoclast precursors compared with those from healthy 
controls [22]. Osteoclast precursors found in the blood of RA patients express higher level of 
Osteoclast Associated Receptor (OSCAR), a co-stimulator of osteoclasts, compared to general 
population [23]. This may lead to a greater capacity for these cells to differentiate into 
osteoclasts. Pro-inflammatory cytokines also create a negative environment within the bone 
by activating local osteoclastogenesis and inhibiting osteoblasts activity [24]. 
 
Extraosseous effect of bisphosphonates 
 
One of the interests for evaluating BPs in the context of arthritis was that, apart from their 
effect on bone, these drugs had demonstrated effects on other pathological processes playing a 
role in the pathogenesis of arthritis such as inflammation, angiogenesis or pain.  
 
Effect on Angiogenesis  
Arthritis development in the joint is associated with an increased angiogenesis. Changes to the 
endothelium are among the first pathophysiological events that occur in the human RA 
synovium with increase in the vascularisation being detected as early as the first month. The 
main cytokine involved in this process is the vascular endothelial growth factor (VEGF), 
produced mainly by the cells of the synovial lining layer. VEGF promotes endothelial 
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migration and proliferation in the synovial tissue [25]. In turn, activated endothelial cells 
express adhesion molecules and present chemokines, leading to leukocyte migration from the 
blood into the pannus tissue [26]. An anti-VEGF-Receptor 1 antibody, tried in the murine 
collagen-induced arthritis (CIA), has suppressed arthritis and decreased the number of 
leukocytes and endothelia cells in the inflammatory tissue [27] 
BPs have been shown, in vitro, to inhibit the main steps of the angiogenic process, from cell 
proliferation to tube formation [3]. This has been demonstrated in a model using human 
umbilical vein and aortic explants [28]. ZA has been showed to induce a long lasting decrease 
in the serum level of VEGF in patients treated for bone metastasis cancer [29]. However, the 
high affinity of BPs to bone may lead in vivo to a short exposure of the endothelial cells to 
BPs. Thus, only high dosage of BPs has demonstrated an antiangiogenic effect in vivo in a 
mouse model of myeloma or prostate cancer[30,31]. In contrast, an equivalent of one year 5 
mg infusion ZA could not inhibit bone vascularisation in a rat model of bone healing [32]. 
Studies are needed to evaluate any potential antiangiogenic effect of BPs in arthritis. 
 
Effect on inflammation 
 
The potential anti-inflammatory effect of BPs is more controversial. They are believed to 
have anti-inflammatory properties but can also induce fever and other inflammatory 
symptoms after infusions. Some data derived from in vitro studies first showed that BPs could 
act on the monocyte/macrophage cells or osteoblast-like cells to inhibit the release of pro-
inflammatory cytokines [33,34]. However, in vivo studies are more contradictory with the 
effect depending on the type of BPs or the model of inflammation [35]. In the context of 
arthritis, two studies using a rat model of collagen-induced arthritis have even demonstrated 
potential pro-inflammatory effects of these drugs when used at high dosage [36,37].  
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One of the most frequent adverse effects with BPs is the acute-phase reaction observed 
mainly after infusion of IV BPs. It is characterised by an influenza-like syndrom with fever, 
myalgia and arthralgia. An increase of serum pro-inflammatory cytokines like IL-6 or TNF 
has been described after BPs infusion. One of the mechanisms suggested for this reaction is 
that the inhibition of the FPP synthase leads to the accumulation of the metabolite upstream 
which is IPP (isopentenyl phosphate) (Figure 1). By an unknown mechanism, IPP is presented 
by the monocytes of the peripheral blood to a subtype of gamma-delta T lymphocytes, 
activating the production of pro-inflammatory cytokines by these cells such as TNF alpha 
[38]. Pre-treatment in vitro by statin prevents such reaction because the statin inhibits the 
mevalonate pathway upstream to IPP [39]. However, a controlled randomized study 
conducted on children had not demonstrated any effect of pre-treatment with atorvastatin on 
pain, CRP or peripheral gamma delta after BPs infusion [40]. 
 
Effect on Pain  
Besides their powerful antiresorptive effect, it is suggested that BPs could also have a specific 
analgesic effect. BPs are known to provide a rapid improvement in pain associated with bone 
metastasis [41]. The most common explanation for that analgesic effect is that, inhibiting 
bone resorption, BPs are able to increase the pH inside the bone microenvironment, resulting 
in a decrease of acid-sensing ion channel nerve stimulation. The analgesic effect could also be 
mediated by the decrease of pro-inflammatory cytokines, prostaglandins, lactic acid, and/or 
various neuropeptides and neuromodulators release during bone degradation which are known 
to stimulate sensitive nerves. As described previously, Nitrogen-containing BPs inhibit the 
prenylation of the GTPases such as Ras, Rac, Rho, and Cdc42 which are involved into the 
postsynaptic plasticity and then signal transmission in the spinal cord [42]. In a mice model of 
pain using the tail flick test (testing the sensitivity of the tail to temperature changing), 
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intravenous BPs have also proved a peripheral antinociceptive effect independent of their 
action on bone although its mechanism remains unclear [43].  
 
Bisphosphonates in the treatment of RA 
 
Treatment and prevention of osteoporosis 
Patients with RA are at greater risk of developing osteoporosis [44]. The increased fracture 
risk is more prominent at the hip and spine and is associated with RA severity, disease 
duration and glucocorticoid use [45]. The mechanism of this bone loss is multifactorial, 
including effects of chronic inflammation on bone, decrease of activity or corticoid use. 
Control of inflammation is important to prevent this bone loss as several studies have 
demonstrated that anti-TNF alpha antibodies were able to prevent bone loss and to increase 
bone formation markers [46,47]. BPs are widely used to prevent or treat osteoporosis 
associated with arthritic conditions. Since they have mainly been evaluated in the context of 
corticoid-induced osteoporosis, a direct action on inflammation-induced bone loss is likely yet 
remains difficult to prove. 
 
Glucocorticoids (GCs) are one of the mainstay therapies for RA, having a rapid anti-
inflammatory effect. They have also been proved to have a beneficial long term effect in the 
prevention of structural damage [48]. However, their use is associated with an increased risk 
of osteoporosis and fractures that is correlated with prolonged or high dose treatment [45]. 
Randomised controlled studies have demonstrated that alendronate and risedronate were 
efficient in the prevention of GCs induced osteoporosis [49,50]. ZA seems to be the most 
efficient in that context. In the HORIZON study, ZA was non-inferior and even superior to 
risedronate at 12 months for increase of lumbar spine bone mineral density (mean 4.06% vs 
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2.71%), even in the patients treated for less than 3 months with GCs (2.60%vs 0.64%). ZA 
showed a faster, more substantial inhibitory effect on bone turnover biomarkers than did 
risedronate [51]. Around 40% of the patients enrolled in this study suffered from RA. Of note, 
about 6-8% of the patients experienced a worsening of their RA in both ZA and risedronate 
group but the absence of any placebo group prevents us to draw any conclusion. Finally, 
although BPs are one of the best options to treat or prevent osteoporosis associated with RA, 
questions remain about the indications and duration of treatment in view of the secondary 
effect associated with their long term use [52]. 
 
Effect of bisphosphonates on clinical and biological parameters of RA 
Several studies have tried to assess any beneficial effect of BPs on clinical symptoms and 
biological inflammation in RA (Table 1) [53-66]. The first work was published in 1988 and 
studied the effect of etidronate 5 mg/kg/day on inflammation [53]. In this study, Bird et al. 
demonstrated an early but transient improvement in clinical index but no effect on serum level 
of inflammatory proteins. In a randomised controlled study, Eggelmeijer et al treated 30 RA 
patients with IV pamidronate (either 20 to 40 mg) and showed a mild but significant decrease 
in clinical inflammation and the level of CRP and ESR with a relation with the dosage use 
[56]. Another study confirmed a potential anti-inflammatory effect of BPs as pamidronate 
1000 mg/day for 12 months significantly decreased the clinical and biological parameters of 
inflammation compared to the placebo [55]. However, pre-existing differences existed in the 
2 groups of treatment in this last study. Since these first studies were published before 1995, 
several authors have failed to see any effect of BPs on inflammatory symptoms [58-63]. The 
relatively small sample size of all studies is likely to result in a lack of power, explaining the 
conflicting results reported. Overall, even if an anti-inflammatory effect exists, the use of BPs 
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in that indication is not justified in view of the efficacy of new treatments to treat 
inflammatory symptoms in RA.  
 
Effect of bisphosphonates in the prevention of bone erosions 
The effect of BPs on bone erosions was initialy assessed in animal model of arthritis. In two 
of them ZA was shown to strongly inhibit focal joint erosions [36,37]. ZA acted directly on 
mature osteoclasts and was able to down regulate the number of osteoclasts inside the joint. 
 
The preliminary encouraging results obtained in animal models were followed by several 
studies that have assessed the effect of BPs on structural damage in RA patients. Maccagno et 
al first demonstrated in 1994 in a double blind controlled study, that a daily dose of oral 
pamidronate prevented bone erosion in RA patients [55]. Indeed, although patients treated 
with BPs had a more active disease before introduction of BPs therapy, they did not show X-
Ray damage after 1 year of pamidronate 1000 mg/day whereas progression was observed in 
the placebo group. Hasegawa et al showed in 31 RA patients treated with cyclic etidronate 
during 1.5 year that this drug was able to prevent the systemic bone loss but also the structural 
damage assessed by the Larsen score compared to the placebo [61]. However, conclusions are 
difficult to draw in view of the small patients sample in the first study and the absence of 
randomization in the second. Moreover, several later studies failed to demonstrate any 
protective effect on bone erosions [62,63]. More recently, one double bind randomized 
controlled proof-of-concept study has compared ZA, the most powerful BP, to placebo in the 
prevention of structural damage [64]. Thirty-nine patients with early RA were randomized to 
receive either two infusions of 5 mg of ZA at 0 and 3 months or a placebo. Bone erosions in 
hand and wrist were assessed with MRI after 6.5 months. The study showed that there were 
61% less erosions in the ZA group compared to control with also a reduction in the number of 
 14 
new erosions. However, these results did not reach statistical significance because of the high 
variability between patients in the evolution of the X-ray score. Since that study, no new 
randomised controlled study have evaluated the effect of BPs in RA, may be because new 
treatments targeting cytokines or intra-cellular pathway have become available. However, the 
lack of superiority of these new treatments in the prevention of bone erosions shows that 
osteoclasts are still a potential therapeutic target in RA. Overall, the effect of BPs on bone 
erosions in RA remains controversial. New randomised studies with more patients and use of 
last generation BPs are necessary to conclude on any beneficial effect in this indication. 
 
Of note, intra-articular injections of BPs have been trialed in RA patients after promising 
preliminary data in animal models of arthritis [65]. Liposome encapsulation of the 
bisphophonates was used as it allows the drug to penetrate in the synovial tissue and have its 
action on the cells in the inflammatory infiltrate. Barrera et al demonstrated in patients with 
longstanding RA that after 2 weeks, the intra-articular injection of clodronate-containing 
liposomes leads to macrophage depletion and decreased expression of adhesion molecules in 
the synovial lining [66]. However, no study has been carried on since that first description. 
 
Long term or high dose BPs are associated with rare but serious adverse effects like 
osteonecrosis of the jaws or the more recently described atypical fractures of the femur. It 
seems that RA patients are not at higher risk to develop such complications. Thus, although 
jaws osteonecrosis has been described in RA patients treated with oral BPs for osteoporosis 
[67,68], there is no evidence of any causal relation between the treatment which was given 
orally at low dose and the occurrence of the osteonecrosis. However, a special care should be 
taken during dental surgical procedure in these patients treated by corticosteroids, having a 
higher risk of parodontopathies. Concerns have also been raised about potential 
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oversuppression of bone turnover and the development of atypical skeletal fragility associated 
with long-term use of BPs [69]. A number of case reports in the literature have documented 
atypical insufficiency fractures in patients on long-term BPs therapy. Someford et al reported 
the case of a RA patient who was treated with alendronate for 8 years and developed 
spontaneous bilateral subtrochanteric/diaphyseal fractures [70]. Being the only case reported 
so far, no conclusion can be drawn but follow-up of RA patients treated with long term BPs 
therapy remains necessary. 
 
Expert commentary 
Their action on osteoclasts and their potential extra-skeletal effects have made BPs an 
attractive alternative therapeutic in arthritis. As underlined in this review, clinical studies have 
been able to only confirm their interest in the treatment and prevention of osteoporosis 
associated with inflammation and corticosteroid use. Any beneficial effect of this treatment 
on inflammation or pain has not been confirmed in patients despite promising in vitro and 
animal data .Their ability to protect from focal joint erosions remains interesting but needs to 
be further explored. ZA, the most potent BP, has shown an interesting potential in a small 
proof-of-principal study in early arthritis. However, although osteoclasts are involved in focal 
and systemic bone loss associated with arthritis, the mechanisms of these two types of bone 
loss may differ and could explain the lack of efficacy observed with BPs in clinical trial. In 
view of the in vivo data, it is likely that higher dosages are needed for BPs to have a beneficial 
effect on bone erosion. As a high variability exists between patients disease, a more targeted 
population of RA patients must be included in the future studies like patients with rapid joint 
destruction or resistant to conventional therapy. Recently, Sojeima et al described a case of a 
38 year old man presenting with a recent rheumatoid arthritis associated with hepatitis C [71]. 
X-Ray of the hands showed erosions and demineralization of the carpus. In view of relative 
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contraindication of immunosuppressive therapy, alendronate was started at the dosage of 5 
mg/day. After 4 months, symptoms and control radiography showed an improvement and 
sometimes healing of bone erosions. However, in the context of potential secondary effects 
associated with high dose or prolonged use of BPs, the justification of any therapeutic has to 
be carefully evaluated. 
 
Five years view 
Although new therapeutics are available to treat RA patients, some patients are still resistant 
to conventional and biological therapy or continue to experience radiological progression 
despite a good control of the disease activity. A complementary treatment may be prescribed 
with the goal to prevent radiological progression. Besides BPs, other therapeutics primarily 
used in osteoporosis should be evaluated in the context of arthritis in the future. Cohen et al 
demonstrated recently that denosumab, a monoclonal antibody targeting RANKL, was able to 
efficiently prevent bone erosions in patients with RA, confirming the therapeutic potential of 
osteoclast inhibition in this indication [72]. If BPs will still be a therapeutic option in this 
indication, dose ranging and a more targeted population of RA needs to be evaluated. 
Moreover, new therapeutic promoting bone formation as anti-sclerostin antibodies will are 
currently trialed in osteoporosis and could also be an alternative solution to not only prevent 
bone erosions but also promotes bone healing [73]. 
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Key issues:  
 
x BPs, targeting osteoclasts, are indicated in all the pathologic processes associated 
with an increase of resorption OLNHRVWHRSRURVLVERQHPHWDVWDVLVRU3DJHW¶VGLVHDVHRI
bone 
x Besides their effect on bone, BPs have extraosseous properties acting on tumor cells, 
inflammation, angiogenesis or pain 
x Inflammatory arthritis is characterised by a chronic inflammation of the joint but is 
also associated with a bone loss 
x Osteoclasts are involved in the local (bone erosions) and systemic (osteoporosis) bone 
loss association with inflammatory arthritis 
x BPs are a therapeutic of choice in the treatment or prevention of osteoporosis 
associated with rheumatoid arthritis 
x Although promising preliminary data are available on the effect of BPs on the 
prevention of joint destruction, more study are needed to confirm a potential 
indication in clinical practice 
x Therapeutic targeting osteoclasts are a therapeutic option in rheumatoid arthritic, 
more particulary in patients with osteoporosis or having rapid joint damage 
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Figure 1. Mechanisms of action of bisphosphonates. Simple-BPs are incorporated with an 
AMP to form an AppCp-type non-hydrolyzable cytotoxic analogues of ATP. The 
mitochondrial ADP/ATP translocase is one of its molecular target, leading to caspase 
activation and apotosis. Nitrogen-containing-BPs (N-BPs) inhibits the farnesyl pyrophosphate 
synthase (FPP Synthase) and geranylgeranyl pyrophosphate synthase (GGPPS) which 
catalyses the condensation of dimethylallyl pyrophosphate (DMAPP) with 2 units of 3-
isopentenyl pyrophosphate (IPP) to form FPP. Accumulated IPP is converted to a cytotoxic 
ATP analogue called ApppI, inducing apoptosis. 
